Abstract: Objective: To summarize the clinical characteristics of Burkitt lymphoma (BL) and Burkitt-like lymphoma (BLL) and the effect of treatment on 13cases, and to explore the treatment-related complications and optimal treatment. Methods:Clinical data of 13BL and BLL patients treated between August 1996and Oc-tober 2008 in our hospital were retrospectively analyzed. All of these patients received chemotherapy as the first-line treatment. The efficacy and adverse reactions were evaluated. Results: Of the 13patients, there were 12males and 1 female, with a median age of 15years (ranging from 11to 62). There were 3 stage Ⅰcases, 2 stage Ⅱcases, 2 stage Ⅲcases, and 6 stage Ⅳcases. The advanced stage (stage Ⅲand Ⅳ) patients ac -counted for61.5% (8 cases). CNS was involved in 4 cases and bone marrow was involved in 2 cases at diag -nosis. The commonly involved sites included superficial lymph nodes (61.5% ), abdominal organs ( 53.8% ), and celiac and retro-peritoneal lymph nodes (38.5%). B symptoms were observed in7 patients (53.8%). Se-rum lactate dehydrogenase level was elevated in 8 of 10cases, while serum uric acid level was elevated in 1 of 10cases. Eleven patients were diagnosed as BL and2 patients were diagnosed as BLL. Of the 13pa-tients, 11(84.6%) achieved complete remission (CR) or CR/unconfirmed (CRu), and 1 patient ( 7.7%) got partial remission (PR). During the follow-up of 8 months (ranging from 5 to 35), 6 patients were still alive. The 1-year overall survival, progression-free survival and disease-free survival were 56.98%,32.31% and 39.77%, respectively. Nine patients (69.2% ) developed grade Ⅲor Ⅳmyelosuppression. Conclusion:Intensive short-course chemotherapy is the optimal first-line treatment for BL and BLL.